| Title: |
Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection |
| Authors: |
Richter, Alex G; Shields, Adrian M; Karim, Abid; Birch, David; Faustini, Sian E; Steadman, Lora; Ward, Kerensa; Plant, Timothy; Reynolds, Gary; Veenith, Tonny; Cunningham, Adam F; Drayson, Mark T; Wraith, David C |
| Contributors: |
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; UKRI |
| Source: |
Clinical & Experimental Immunology ; volume 205, issue 2, page 99-105 ; ISSN 0009-9104 1365-2249 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2021 |
| Description: |
Summary Coronavirus 19 (COVID-19) has been associated with both transient and persistent systemic symptoms that do not appear to be a direct consequence of viral infection. The generation of autoantibodies has been proposed as a mechanism to explain these symptoms. To understand the prevalence of autoantibodies associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we investigated the frequency and specificity of clinically relevant autoantibodies in 84 individuals previously infected with SARS-CoV-2, suffering from COVID-19 of varying severity in both the acute and convalescent setting. These were compared with results from 32 individuals who were on the intensive therapy unit (ITU) for non-COVID reasons. We demonstrate a higher frequency of autoantibodies in the COVID-19 ITU group compared with non-COVID-19 ITU disease control patients and that autoantibodies were also found in the serum 3–5 months post-COVID-19 infection. Non-COVID patients displayed a diverse pattern of autoantibodies; in contrast, the COVID-19 groups had a more restricted panel of autoantibodies including skin, skeletal muscle and cardiac antibodies. Our results demonstrate that respiratory viral infection with SARS-CoV-2 is associated with the detection of a limited profile of tissue-specific autoantibodies, detectable using routine clinical immunology assays. Further studies are required to determine whether these autoantibodies are specific to SARS-CoV-2 or a phenomenon arising from severe viral infections and to determine the clinical significance of these autoantibodies. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1111/cei.13623 |
| Availability: |
https://doi.org/10.1111/cei.13623; https://onlinelibrary.wiley.com/doi/pdf/10.1111/cei.13623; https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cei.13623; https://academic.oup.com/cei/article-pdf/205/2/99/51098651/cei13623.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.35AD0A21 |
| Database: |
BASE |